How do pediatric endocrinology clinic nurses explain to Spanish-speaking parents why levothyroxine must continue when their child with thyroid agenesis has had a normal TSH for eighteen months?

The explanation requires establishing precisely what a normal TSH means in a child with thyroid agenesis and distinguishing it from the meaning parents commonly assume. Thyroid agenesis is the embryonic failure of thyroid bud differentiation and migration that produces a complete absence of thyroid follicular cells. The thyroid gland does not exist in the thyroid bed, confirmed by nuclear imaging showing no uptake in the neck or elsewhere. Without follicular cells there is no NIS transporter to concentrate iodide, no thyroglobulin scaffold on which to iodinate tyrosine residues, no iodothyronine coupling to form T4, and no colloid reservoir from which T4 and T3 can be proteolytically released into the bloodstream. The thyroid gland produces zero T4 and zero T3. It was producing zero T4 and zero T3 the day Isabella was born and will produce zero T4 and zero T3 every day of her life. Levothyroxine is synthetic T4 — the identical molecule to the T4 that a person with a normally functioning thyroid gland produces endogenously. It is not a supplement to thyroid activity. It is the thyroid hormone. When Isabella takes 75 mcg of levothyroxine each morning, it is absorbed in the small intestine, enters the portal circulation, reaches the liver where a fraction is converted to T3 by type I deiodinase, and distributes throughout the body. In the pituitary gland, the thyrotroph cells sense the circulating T4 and T3 concentration through TRβ nuclear receptors. When the T4 concentration is sufficient — as it is when Isabella takes the correct dose — TRβ binding activates transcriptional programs that suppress TSH secretion and TSH synthesis. TSH 1.8 mIU/L is the pituitary reporting that it senses adequate circulating T4. The pituitary is not asking whether that T4 came from the thyroid gland or from a tablet — it cannot distinguish the source. It receives the signal and responds correctly. TSH 1.8 is not evidence that Isabella's thyroid is working. It is evidence that Isabella's levothyroxine dose is calibrated correctly. If levothyroxine stops, the T4 source is removed. The plasma half-life of T4 is six to seven days. After the first week without medication, free T4 has fallen approximately 50 percent. By two to three weeks, free T4 is below the lower reference limit. The pituitary, no longer sensing adequate T4, upregulates TSH secretion. TSH rises above 10 mIU/L within three to four weeks. By five to six weeks, Isabella has overt hypothyroidism: free T4 below 0.7 ng/dL, TSH above 10. In a six-year-old, this matters for brain development in ways that are not visible as a sudden crisis. T3 (the active intracellular hormone derived from T4) regulates the expression of myelin basic protein, myelin-associated glycoprotein, and proteolipid protein in oligodendrocytes through TRα1 nuclear receptor binding. Active myelination continues in the human brain until approximately age eight to ten. Hypothyroidism slows myelin synthesis and impairs the columnar organization of white matter tracts. T3 also regulates dendritic arborization and synaptogenesis in the prefrontal cortex and hippocampus — both areas undergoing active structural development in a six-year-old. The original motivation for neonatal thyroid screening programs was the prevention of cretinism, the irreversible intellectual disability caused by untreated congenital hypothyroidism throughout early childhood: the IQ loss from severe untreated hypothyroidism is 30 to 50 points. Neonatal screening and early levothyroxine initiation before day 14 of life eliminated this outcome. That outcome does not stay eliminated if levothyroxine is stopped. The protective effect is maintained only while the hormone is present.

How do pediatric endocrinology clinic nurses explain to Spanish-speaking parents why the stress-dosing protocol for congenital adrenal hyperplasia must continue after two febrile illnesses without visible adrenal crisis?

The explanation requires establishing what cortisol does during physiologic stress, why CYP21A2 deficiency makes a cortisol surge biologically impossible, and then explaining why two illnesses without crisis does not mean the stress dosing protocol is unnecessary. CYP21A2 encodes 21-hydroxylase, the enzyme that converts 17-hydroxyprogesterone to 11-deoxycortisol in the glucocorticoid pathway. Without functional 21-hydroxylase, the entire pathway from cholesterol to cortisol is blocked at this step. Marco's compound heterozygous genotype — one allele retaining one to two percent of normal activity, one null allele — produces less than two percent of normal 21-hydroxylase activity. For practical purposes, cortisol synthesis is zero. No amount of ACTH stimulation, no amount of illness severity, no amount of physiologic demand can cause Marco's adrenal cortex to produce a cortisol surge. The precursors 17-OHP and androstenedione accumulate in vast excess, but cortisol does not appear. Under normal physiologic conditions, the hypothalamic-pituitary-adrenal axis produces a basal cortisol secretion of approximately 6 to 8 mg per square meter per day with a diurnal morning peak. This is what the maintenance hydrocortisone dose approximates. But during physiologic stress — fever above 38.5 degrees Celsius, an infection requiring an inflammatory response, trauma, or surgery — a person with intact adrenal function produces a cortisol surge three to ten times the baseline level within thirty minutes. This stress surge reaches 30 to 50 micrograms per deciliter and serves three simultaneous critical functions. First, cortisol upregulates alpha-1 and beta-1 adrenergic receptor expression on vascular smooth muscle cells and cardiomyocytes and potentiates the vasoconstrictive and inotropic effects of circulating catecholamines. This is why blood pressure maintenance during sepsis depends on cortisol: the vasopressors do not work effectively without cortisol sensitizing the target receptors. In adrenal insufficiency without cortisol replacement, vasodilatory hypotension does not respond to fluid resuscitation or standard vasopressor doses. Second, cortisol stimulates hepatic gluconeogenesis through upregulation of PEPCK and glucose-6-phosphatase and inhibits peripheral glucose uptake, maintaining blood glucose during the relative fast of illness when feeding is reduced and metabolic demand is elevated. Without this gluconeogenic stimulus, blood glucose falls. In a four-year-old with high metabolic rate per kilogram, hypoglycemia during febrile illness can develop within hours. Third, cortisol regulates free water clearance by modulating ADH suppression. Without cortisol, ADH secretion becomes disproportionate to serum osmolality, producing dilutional hyponatremia even on fludrocortisone, which compensates for the aldosterone deficit but cannot replace cortisol's ADH regulatory function. Marco's adrenal gland cannot execute any of these three responses during illness. If the stress dosing protocol is not followed during a febrile illness, Marco receives only his maintenance hydrocortisone — the dose designed for basal needs, not for a physiologic stress surge. The two illnesses Roberto describes as tolerated without stress dosing almost certainly represent illnesses in which the physiologic stress demand stayed within the range that maintenance hydrocortisone could cover. A mild otitis media with low-grade fever may not have required a full stress cortisol surge to maintain vascular tone and blood glucose above crisis thresholds. The maintenance dose reserve was sufficient. This is not evidence that the stress dosing is unnecessary. It is evidence that those two specific illnesses fell below the threshold. The next illness that pushes physiologic demand above the maintenance reserve will produce adrenal crisis from the same absent cortisol synthesis. There is no way for Roberto to know, from watching Marco at home during a fever, whether the physiologic demand is within the maintenance reserve or approaching crisis threshold — because the early signs of adrenal insufficiency (fatigue, lethargy, poor appetite, abdominal pain) are identical to the normal signs of a viral illness in a four-year-old. The clinical distinction appears only when crisis is established: refractory hypotension, hypoglycemia, altered consciousness. Adrenal crisis mortality before hydrocortisone administration historically reaches 25 to 50 percent. After prompt intramuscular hydrocortisone 50 mg per square meter, adrenal crisis from isolated adrenal insufficiency has near-zero mortality. The stress dosing protocol — three times the daily dose orally for fever above 38.5 degrees, IM hydrocortisone and immediate emergency visit if oral medication cannot be tolerated — is the mechanism that prevents adrenal crisis. It is not a precautionary ritual based on theoretical risk. It is the cortisol replacement that makes physiologic stress survivable for a child whose adrenal gland permanently cannot respond to it.

How do pediatric endocrinology clinic nurses explain to Spanish-speaking parents why growth hormone injections must continue when their child with GH deficiency post-craniopharyngioma is growing at a normal rate?

The explanation requires establishing what craniopharyngioma surgery does to somatotroph cells, why somatotrophs do not recover, and then making clear that normal growth velocity IS the injections working and reflects nothing about pituitary recovery. The pituitary gland's anterior lobe contains five cell populations producing distinct hormones. Somatotrophs, which produce growth hormone, comprise 40 to 50 percent of anterior pituitary cell mass and are concentrated in the lateral wings. Craniopharyngioma — a benign but locally destructive epithelial tumor arising from Rathke's pouch remnants in the suprasellar region — damages somatotrophs through two mechanisms. As the tumor expands in the confined suprasellar space, it compresses the pituitary stalk and the anterior pituitary, progressively ischemic pressure-necrosis of somatotroph cell bodies. During transsphenoidal surgical resection, the approach requires cutting through or retracting the pituitary stalk, which carries the portal blood supply from hypothalamic neurons to the anterior pituitary, including the GHRH-secreting neurons in the arcuate nucleus. After tumor removal, many patients have partial or complete stalk transection producing hypopituitarism across multiple axes. Sofia's post-surgical insulin tolerance test, the gold-standard GH stimulation test, produced a peak GH of 0.4 nanograms per milliliter. Normal peak GH on ITT exceeds 10 ng/mL; the pediatric cut-off for severe GH deficiency is peak GH below 3 to 5 ng/mL depending on BMI and assay. At 0.4 ng/mL, Sofia's somatotroph response is effectively zero. Her IGF-1 at diagnosis was 42 ng/mL at an SDS of minus 3.1, confirming that her liver was receiving no meaningful GH signal before treatment. Adult somatotrophs have minimal capacity for regeneration after destruction. Unlike the thyroid, which has some follicular regeneration capacity after minor injury, anterior pituitary somatotrophs have essentially no progenitor cell replacement in the post-childhood period. The post-surgical MRI showing pituitary stalk thickening or empty sella is structural evidence of permanent anatomical disruption. Sofia will never produce meaningful GH from her own pituitary again. Recombinant human GH binds GH receptors on hepatocytes and activates the JAK2-STAT5 intracellular signaling pathway, which translocates to the nucleus and transactivates IGF-1 gene expression. The hepatocytes secrete IGF-1 into the bloodstream. IGF-1 binds IGF1R receptors on epiphyseal growth plate chondrocytes in the proliferative and hypertrophic zones, driving chondrocyte proliferation and matrix synthesis that constitutes longitudinal bone growth. GH also directly stimulates periosteal bone modeling and IGF-1 promotes bone mineral density accrual across the skeleton. Sofia's height velocity rose from 2.8 centimeters per year before treatment to 8.6 centimeters per year on GH — which reflects the GH injections supplying the IGF-1 signal that her absent pituitary GH secretion cannot provide. Her mother is correct that 8.6 centimeters per year is normal height velocity for a nine-year-old girl. That is exactly the evidence that the GH is working. If GH therapy is stopped, IGF-1 falls from the treated level of SDS minus 0.4 back toward the pre-treatment level of SDS minus 3.1 within six weeks, because hepatic IGF-1 production reflects current GH stimulation and not a reservoir. Height velocity returns to approximately 2.8 centimeters per year within three to six months. Sofia is nine years old. Girls typically complete epiphyseal closure between ages 15 and 17. She has six to eight years of GH-dependent linear growth ahead of her. At 2.8 centimeters per year for six to eight years she would gain 17 to 22 centimeters of additional height. At 8.6 centimeters per year for six to eight years she would gain 52 to 69 centimeters. The difference in final adult height is approximately 15 to 20 centimeters below her mid-parental height target — roughly the difference between an adult stature that falls within the normal range for her family and one that does not. Beyond height, GH throughout adolescence is required for bone mineral density accrual — the peak bone mass achieved by age 25 to 30 determines fracture risk for the rest of life. GH deficiency during adolescence reduces peak bone mass independent of dietary calcium, and the risk cannot be fully recovered after epiphyseal closure. The daily injections that Sofia finds burdensome are the GH her pituitary permanently cannot provide. The growth the family celebrates as evidence she can stop is the most precise possible evidence that she cannot.

What are the key clinical Spanish phrases for the pediatric endocrinology clinic covering levothyroxine continuation in thyroid agenesis, stress dosing in CAH, and GH injections post-craniopharyngioma?

For explaining levothyroxine continuation when TSH is normal in thyroid agenesis: 'El TSH normal de Isabella NO significa que su tiroides está funcionando — significa que la dosis de levotiroxina está calibrada correctamente. La tiroides de Isabella no existe: no hay células foliculares que produzcan hormona tiroidea. La levotiroxina ES la hormona tiroidea que Isabella necesita, no un suplemento para ayudar a una tiroides débil. Cuando dejamos la levotiroxina, la hormona T4 cae en dos a tres semanas, el TSH sube por encima de 10 en cuatro semanas, y el cerebro de Isabella, que todavía está mielinizando activamente hasta los ocho o diez años, deja de recibir la señal hormonal que necesita para ese proceso.' (Isabella's normal TSH does NOT mean her thyroid is working — it means the levothyroxine dose is calibrated correctly. Isabella's thyroid does not exist: there are no follicular cells to produce thyroid hormone. Levothyroxine IS the thyroid hormone Isabella requires, not a supplement to help a weak thyroid. When we stop levothyroxine, T4 hormone falls in two to three weeks, TSH rises above 10 in four weeks, and Isabella's brain, which is still actively myelinating until age eight to ten, stops receiving the hormonal signal it needs for that process.) For explaining CAH stress dosing: 'La deficiencia de 21-hidroxilasa de Marco le impide permanentemente producir cortisol en cualquier cantidad. Cuando hay fiebre o enfermedad, el cuerpo normal produce de tres a diez veces más cortisol que en reposo para mantener la presión arterial y el azúcar en sangre. El cuerpo de Marco no puede hacer eso — la enzima no existe. Las dos enfermedades anteriores probablemente fueron lo suficientemente leves como para que la dosis de mantenimiento alcanzara. La próxima infección que exija más tendrá un resultado diferente si no duplicamos la dosis. La crisis suprarrenal puede comenzar con hipotensión y convulsiones en horas. El protocolo de estrés es el mecanismo que impide la crisis, no una precaución opcional.' (Marco's 21-hydroxylase deficiency permanently prevents him from producing any cortisol. When there is fever or illness, the normal body produces three to ten times more cortisol than at rest to maintain blood pressure and blood sugar. Marco's body cannot do that — the enzyme does not exist. The two previous illnesses were likely mild enough that the maintenance dose was sufficient. The next infection that demands more will have a different result if we do not triple the dose. Adrenal crisis can begin with hypotension and seizures within hours. The stress protocol is the mechanism that prevents crisis, not an optional precaution.) For explaining GH injections when growth looks normal post-craniopharyngioma: 'Las células productoras de hormona de crecimiento de Sofia fueron destruidas por el tumor y la cirugía. No se regeneran. El crecimiento de 8.6 centímetros por año que su mamá está viendo ES las inyecciones funcionando — es exactamente lo que muestra que la dosis es correcta. Si paramos las inyecciones, el IGF-1 cae a los niveles de antes del tratamiento en seis semanas y la velocidad de crecimiento vuelve a 2.8 centímetros al año en pocos meses. Sofia tiene nueve años y sus huesos todavía están creciendo. Sin las inyecciones, su estatura final sería de 15 a 20 centímetros menos de lo esperado para su familia. El crecimiento normal que la familia celebra es la mejor evidencia de que las inyecciones están funcionando, no de que ya no las necesita.' (Sofia's growth hormone-producing cells were destroyed by the tumor and surgery. They do not regenerate. The 8.6 centimeters per year growth that her mom is seeing IS the injections working — it is exactly what shows that the dose is correct. If we stop the injections, IGF-1 falls to pre-treatment levels in six weeks and growth velocity returns to 2.8 centimeters per year within a few months. Sofia is nine years old and her bones are still growing. Without the injections, her final height would be 15 to 20 centimeters less than expected for her family. The normal growth the family celebrates is the best evidence that the injections are working, not that she no longer needs them.)

What are the most important communication challenges for Spanish-speaking families in the pediatric endocrinology clinic that translated handouts cannot adequately address?

Three structural communication challenges recur in pediatric endocrinology encounters with Spanish-speaking families and are not adequately addressed by translated educational materials alone. The first is the normal-lab-result-as-disease-resolution inference in congenital hypothyroidism. A normal TSH is the most concrete, number-based indicator of treatment success that families see at clinic visits. In every other medical context a family member may have encountered, a normal test result means the problem is resolved or absent. In thyroid agenesis, a normal TSH means the levothyroxine dose is correctly calibrated — the exact inverse of the inference the family naturally makes. Consumer health information about thyroid disease, which predominantly describes Hashimoto's thyroiditis and subacute thyroiditis in adults, reinforces the association between TSH normalization and thyroid function recovery. A parent who encounters this information arrives at clinic with a specific model: TSH was high because the thyroid was sick; TSH is now normal because the thyroid recovered. The translated handout that says 'continue levothyroxine as prescribed' cannot displace this model without explaining why the normal TSH means precisely the opposite in thyroid agenesis versus hypothyroidism from recoverable causes. The nurse who can say 'the normal TSH is the medication level set exactly right; it would be normal if there were no thyroid at all and you were giving the correct dose because the pituitary only measures the hormone level, not where it came from' is delivering the specific conceptual correction that changes how the family interprets every future normal TSH result. The second challenge is the threshold-invisibility problem in CAH stress dosing. The family's direct experience — Marco survived two febrile illnesses without stress dosing — is the strongest possible experiential evidence available to them that the protocol is not necessary. This experience is accurate and honestly reported. The critical information they lack is about the threshold: that physiologic demand during illness varies by illness severity, that maintenance hydrocortisone covers a range of demand up to a threshold, and that adrenal crisis begins when demand crosses that threshold. The family cannot see, feel, or measure which illnesses fell below the threshold and which illness is approaching it. The nurse who explains 'the two previous illnesses were probably mild enough that Marco's maintenance dose was enough — it doesn't mean the protocol is unnecessary, it means those two illnesses didn't demand more than the maintenance level could provide. We can't tell which illness will be more demanding until the crisis starts, and by then we need the stress dose to already be in his system' is explaining threshold-invisibility in terms that convert the family's experience from a data point against the protocol to a data point about illness variability that confirms why the protocol exists. The third challenge is the mechanism-invisibility of GH therapy in growth hormone deficiency. The family's observation that their daughter is growing normally is accurate, celebrated, and the direct result of successful treatment. In most childhood medical contexts, normalization of a clinical parameter means the illness is resolving and treatment can be considered for reduction. A family that has watched their daughter go from 2.8 centimeters per year — clearly abnormal, clearly distressing — to 8.6 centimeters per year — clearly normal, clearly a relief — has no experiential basis for understanding that the normal growth is the treatment working continuously and not evidence of pituitary recovery. The missing concept is mechanism-dependence: the growth velocity at any moment reflects the GH signal present in the preceding weeks, and the GH signal is entirely supplied by the injections because the pituitary somatotrophs are permanently non-functional. There is no reservoir, no partial recovery, no gradual improvement — just the injection providing the daily signal and the normal growth reflecting it. The nurse who reframes 'growing normally' from 'the pituitary is working again' to 'the injections are working exactly as intended — the growth you're seeing is the direct product of each injection, and it stops when the injections stop' is providing the mechanistic connection that makes continued daily injections make sense when normal growth makes stopping feel intuitive.

Spanish for pediatric endocrinology clinic nurses — congenital hypothyroidism levothyroxine continuation, congenital adrenal hyperplasia stress dosing, and growth hormone deficiency post-craniopharyngioma

Three families in the pediatric endocrinology clinic share a structural communication challenge: each family observes a positive clinical measurement — a normal TSH, two febrile illnesses survived without crisis, a child growing at a normal rate — and each family reasons from that measurement toward reducing or stopping a treatment, not knowing that the positive measurement either confirms the treatment is working correctly or reflects the accumulation of near-misses that fell below a threshold the next illness may cross. Isabella’s TSH of 1.8 mIU/L is the pituitary reporting that it senses adequate circulating T4 from the levothyroxine; the thyroid gland producing zero T4 is unchanged. Marco’s two survived febrile illnesses reflect illnesses that likely did not demand a cortisol surge beyond what maintenance hydrocortisone provides; the CYP21A2 genotype is the same as it was during both, and the next illness that demands more will encounter the same cortisol synthesis capability: zero. Sofia’s 8.6 cm/year height velocity is IGF-1 from GH injections stimulating epiphyseal chondrocyte proliferation in growth plates; the somatotroph cells destroyed by craniopharyngioma and surgery have not returned, and stopping injections removes the only source of GH her body will ever have.

Isabella Reyes-Castillo, 6 years old, Houston, Texas — thyroid agenesis, levothyroxine 75 mcg/day, TSH 1.8 mIU/L and free T4 1.3 ng/dL stable 18 months, mother requesting discontinuation

Isabella was identified on day three of life by the Texas newborn screening program: TSH 98 mIU/L on the dried blood spot filter paper, well above the cut-off, with confirmatory free T4 of 0.4 ng/dL. I-123 thyroid scintigraphy at three weeks demonstrated no uptake in the thyroid bed, no ectopic lingual thyroid tissue, no substernal uptake. The diagnosis: thyroid agenesis — embryonic failure of the thyroid bud to differentiate from the floor of the pharynx and migrate caudally to its position in the neck. The thyroid gland does not exist in any location, confirmed structurally by neck ultrasound showing no thyroid tissue.

Levothyroxine was started at day twelve — within the critical window the American Academy of Pediatrics defines for neurodevelopmental protection. The starting dose was 50 mcg/day. Over six years it has been titrated upward as Isabella’s weight increased and the proportional dose requirement stabilized, reaching the current 75 mcg/day. Monitoring every four to six months: TSH and free T4. Eighteen consecutive months of normal results: TSH ranging 1.4 to 2.1 mIU/L, free T4 ranging 1.1 to 1.4 ng/dL.

Today her mother, Mariela Reyes-Torres, thirty-one, home daycare provider, brings in a YouTube video on her phone. A wellness channel she follows described how hypothyroidism can “heal with the right nutrition and supplements” and showed testimonials of adults who normalized their TSH and reduced their thyroid medication. Mariela is clear and specific: Isabella’s TSH has been normal for a year and a half. She wants to know if the thyroid has recovered and whether the levothyroxine can be stopped or at least reduced.

Nurse Elena Torres-García recognizes that the information on Mariela’s phone is accurate for adults with Hashimoto’s thyroiditis, where thyroid function sometimes partially recovers after the inflammatory phase, and meaningless for thyroid agenesis, where there is no thyroid tissue to recover. The explanation begins with exactly what a normal TSH in thyroid agenesis actually reports.

Thyroid hormone synthesis is a multi-step process that depends entirely on thyroid follicular cells. These cells concentrate iodide from the bloodstream through the sodium-iodide symporter (NIS) on their basolateral membrane. They produce thyroglobulin — the large glycoprotein scaffold that contains approximately 123 tyrosine residues available for iodination. Thyroid peroxidase (TPO) on the apical surface oxidizes iodide to iodine and catalyzes the iodination of tyrosine residues in thyroglobulin to form monoiodotyrosine (MIT) and diiodotyrosine (DIT). Coupling of two DIT residues produces T4 (thyroxine); coupling of MIT and DIT produces T3 (triiodothyronine). The iodinated thyroglobulin is stored in the follicular lumen as colloid. TSH stimulation triggers endocytosis of colloid back into the follicular cell, lysosomal proteolysis of thyroglobulin to release T4 and T3, and secretion of these hormones into the bloodstream.

Without follicular cells, none of this occurs. There is no NIS to concentrate iodide. There is no thyroglobulin. There is no TPO. There is no colloid. Isabella’s thyroid bed has no cells, no vasculature serving them, no functional architecture. Her thyroid produces zero T4 and zero T3. It did so the day she was born and will do so every day of her life. No nutrient, no supplement, no iodine source, no wellness protocol changes this. The cells that would perform this synthesis never differentiated.

Levothyroxine is the synthetic form of T4 — identical in structure to the T4 a person with a normally functioning thyroid produces. It is not an adjunct to a functioning thyroid. It is not a signal to stimulate thyroid activity. It is the T4 Isabella’s body requires for every cellular function that depends on thyroid hormone. After oral absorption in the small intestine (bioavailability approximately 70 to 80 percent when taken on an empty stomach, reduced by calcium, iron, and certain foods), levothyroxine enters the portal circulation. In peripheral tissues — primarily the liver, kidney, skeletal muscle, and heart — type I deiodinase (DIO1) removes the outer-ring iodine from T4 to produce T3, the active intracellular form that binds thyroid hormone receptors (TRα and TRβ) in target cell nuclei.

The pituitary thyrotroph cells continuously monitor the circulating T4 and T3 concentration through their own nuclear TRβ2 receptors. When T4 concentration is within the adequate range, TRβ2 binding activates a transcriptional program that suppresses both TSH gene expression and TSH secretion from thyrotroph granules. TSH 1.8 mIU/L is the pituitary reporting that its TRβ2 receptors are sensing adequate free T4. It makes this report without any information about whether that T4 came from a thyroid gland or a tablet. The receptor measures the concentration of the hormone molecule, not its origin.

TSH 1.8 in thyroid agenesis is therefore not evidence of thyroid recovery. There is nothing to recover from and nothing to recover to. There are no follicular cells injured and resting. TSH 1.8 is evidence that Isabella’s levothyroxine dose is currently calibrated correctly — that 75 mcg/day is providing the T4 concentration her body requires and that her pituitary is confirming that the signal is adequate.

If levothyroxine is stopped, T4 is no longer entering Isabella’s circulation. The plasma half-life of T4 is six to seven days. After the first week, free T4 has fallen approximately 50 percent from its current 1.3 ng/dL to approximately 0.65 ng/dL — below the lower reference limit. Pituitary thyrotrophs, no longer sensing adequate T4 at their TRβ2 receptors, upregulate TSH gene expression and begin releasing stored TSH. By three to four weeks, TSH rises above 10 mIU/L. By five to six weeks, free T4 reaches hypothyroid levels below 0.7 ng/dL.

In a six-year-old, this progression matters for brain development in ways that do not present as acute visible symptoms. The active hormone T3, binding TRα1 nuclear receptors in oligodendrocytes, upregulates the genes encoding myelin basic protein, myelin-associated glycoprotein, and proteolipid protein — the structural proteins that form the myelin sheath around axons. Myelination in the human brain is not complete at birth. Active myelination continues in the frontal white matter and association fibers until approximately age eight to ten. A six-year-old is in the middle of this window. Hypothyroidism during active myelination slows the expression of myelin structural proteins and impairs the ordered columnar organization of myelin lamellae, producing subtle white matter abnormalities that are not visible on physical examination and do not produce an acute neurological event.

T3 also regulates dendritic arborization and synaptogenesis in the prefrontal cortex and hippocampus through TRα1-mediated regulation of cytoskeletal proteins, neurotrophins, and adhesion molecules. The prefrontal cortex is undergoing active synaptic pruning and consolidation during ages six to ten — the neurological process that underlies executive function, working memory, and impulse regulation. The hippocampus is the critical structure for declarative memory consolidation throughout childhood. Hypothyroidism during this period disrupts the hormonal milieu these developmental processes depend on.

The scale of the risk is set by history: cretinism — the severe irreversible intellectual disability, short stature, and deafness produced by untreated congenital hypothyroidism throughout early childhood — was eliminated as an outcome in developed countries by neonatal thyroid screening programs introduced in the 1970s and 1980s. The elimination required only early levothyroxine initiation before day 14 of life and continuous maintenance thereafter. Isabella benefited from screening and early treatment and has developed normally because of those six years of continuous levothyroxine. That outcome is maintained only as long as the T4 is present. The YouTube testimonials Mariela watched describe adults with Hashimoto’s thyroiditis — an autoimmune inflammatory disease of an existing thyroid gland that sometimes partially resolves. Isabella has no thyroid gland. The mechanism of those testimonials does not apply to her in any way.

Nurse Elena gives Mariela a single concrete reframe: the normal TSH is the levothyroxine dose set exactly right. If we took out the levothyroxine and replaced it with water for six weeks and then measured the TSH, it would be above 50. That number tells you there is no thyroid. The number 1.8 tells you the dose is correct. Both numbers are about the medication — zero of either number is about the thyroid.

Marco Cisneros-Herrera, 4 years old, San Antonio, Texas — classic salt-wasting CAH, CYP21A2 compound heterozygous, stress-dosing protocol discontinued by father after two mild illnesses

Marco was diagnosed in the newborn period through Texas critical congenital heart disease screening that prompted additional endocrine workup after an abnormal presentation. His 17-hydroxyprogesterone (17-OHP) on day four was 820 nmol/L (normal newborn <30 nmol/L, salt-wasting CAH typically >300 nmol/L). Androstenedione was grossly elevated. CYP21A2 molecular testing identified compound heterozygous pathogenic variants: p.Ile172Asn on the maternal allele and p.Gln318* on the paternal allele. The p.Ile172Asn variant produces approximately one to two percent of normal 21-hydroxylase activity; p.Gln318* is a null allele. Combined, Marco’s 21-hydroxylase activity is less than two percent of normal.

He has been on maintenance hydrocortisone 6 mg/m²/day divided three times daily, fludrocortisone 0.1 mg/day, and sodium chloride supplementation since the newborn period. Monitoring every three to four months: 17-OHP, androstenedione, plasma renin activity, blood pressure, height, weight, and bone age annually. Current control: 17-OHP 8.2 nmol/L (within target range of 2–20 nmol/L), androstenedione 0.9 nmol/L, plasma renin activity normal on current fludrocortisone dose.

The stress-dosing protocol the clinic provided: triple the daily hydrocortisone dose (to approximately 18 mg/m²/day) at the first sign of fever above 38.5°C, vomiting, or significant illness; administer an emergency injectable hydrocortisone 50 mg/m² IM if Marco cannot retain oral doses and immediately go to the emergency department; do not wait to see if he improves. Roberto Cisneros-Torres, forty-three, warehouse supervisor, describes two febrile illnesses in the past year — an acute otitis media and an upper respiratory viral illness — during which he was uncertain about the stress dosing, waited to see how Marco responded, and concluded that Marco did fine without it. He finds the protocol anxiety-provoking and believes it may be overly conservative. He wants to know if it is necessary.

Nurse Carmen Fuentes-Vásquez understands that Roberto’s experience is real: Marco did not have a visible adrenal crisis. The conversation requires establishing why that observation does not mean the protocol is optional.

CYP21A2 encodes steroid 21-hydroxylase, a cytochrome P450 enzyme (P450c21) located in the endoplasmic reticulum of adrenal cortex cells. 21-hydroxylase is the sole enzyme catalyzing the conversion of 17-hydroxyprogesterone to 11-deoxycortisol in the glucocorticoid biosynthetic pathway. Without this step, 11-deoxycortisol cannot be produced, cortisol synthase (P450c11) has no substrate, and cortisol is never synthesized. Simultaneously, 21-hydroxylase converts progesterone to 11-deoxycorticosterone in the mineralocorticoid pathway; without this step, aldosterone synthesis is also blocked (hence salt-wasting). The enzyme-blocking variants Marco carries produce less than two percent of normal 21-hydroxylase activity in the zona fasciculata cells of the adrenal cortex. For practical purposes, Marco’s adrenal gland cannot produce measurable cortisol in response to any level of ACTH stimulation. ACTH can rise to any level — in severe illness, ACTH can rise fifty to one hundred times the baseline — and Marco’s adrenal will not respond with cortisol, because the precursor conversion step is absent.

Under basal conditions, the hypothalamic-pituitary-adrenal axis produces a diurnal cortisol secretion of approximately 6 to 8 mg/m²/day, peaking at approximately 8 AM and nadir in the early morning hours. Hydrocortisone 6 mg/m²/day approximates this basal requirement. This dose maintains adequate cortisol-dependent vascular tone, blood glucose regulation, and immune modulation during ordinary daily activity. It is not designed to provide the physiologic stress response.

During acute illness — fever, infection, trauma, or surgery — a person with intact adrenal function experiences a rapid ACTH surge within fifteen to thirty minutes of the physiologic insult. The adrenal responds with a cortisol surge three to ten times the baseline level: peak stress cortisol reaches 30 to 50 mcg/dL (compared to a normal morning peak of approximately 20 mcg/dL) and is sustained for the duration of the acute stress period. This stress cortisol serves three simultaneous functions that are essential for surviving acute illness.

The first is vascular competence. Cortisol upregulates the expression of α1-adrenergic and β1-adrenergic receptors on vascular smooth muscle cells and cardiomyocytes at the transcriptional level through glucocorticoid response elements in their promoter regions. Without cortisol, receptor density on vascular smooth muscle is below the level needed for catecholamines — epinephrine and norepinephrine — to maintain vasoconstriction effectively. In adrenal crisis, the hypotension is characteristically vasodilatory and catecholamine-refractory: infusions of norepinephrine that would restore blood pressure in septic shock from preserved adrenal function do not work in adrenal crisis because the receptors the norepinephrine must bind are underexpressed. Fluid resuscitation alone does not correct it. Only cortisol replacement restores the vascular responsiveness that makes pressors effective.

The second is blood glucose maintenance. Cortisol stimulates hepatic gluconeogenesis by upregulating phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase in hepatocytes, enabling the liver to produce glucose from amino acids, glycerol, and lactate. It also inhibits peripheral glucose uptake and insulin sensitivity in muscle and adipose tissue during the acute stress period, directing glucose toward high-priority organs (brain, heart). Without this gluconeogenic stimulus during febrile illness — when feeding is reduced and metabolic rate is elevated by fever — blood glucose falls. In a four-year-old with a high metabolic rate per kilogram, hypoglycemia from adrenal insufficiency can develop within hours of a febrile illness onset.

The third is free water balance. Cortisol is required for normal suppression of arginine vasopressin (ADH) secretion in response to serum osmolality. Without cortisol, ADH secretion becomes disproportionate to serum osmolality, producing dilutional hyponatremia even in a child who is on fludrocortisone — which compensates for the mineralocorticoid aldosterone deficit but does not replace cortisol’s role in ADH regulation. Hyponatremia in adrenal crisis can produce cerebral edema and seizures in a child.

Marco’s adrenal gland cannot execute any of these responses. The same CYP21A2 genotype that produces less than two percent of normal 21-hydroxylase activity today produced less than two percent during both of Marco’s prior illnesses. What differed between those illnesses and a crisis-producing illness is the magnitude of physiologic demand. The oral otitis media and the upper respiratory viral infection in Marco’s history were likely characterized by low-grade fever, modest metabolic rate elevation, adequate oral intake, and a physiologic stress demand that remained within the range the maintenance hydrocortisone dose could cover. The maintenance dose was providing approximately the basal cortisol requirement; the illness’s demand did not exceed the basal reserve enough to produce vasodilatory hypotension or hypoglycemia. This is a statement about those two specific illnesses, not about Marco’s cortisol synthesis capability, which remains zero.

Roberto cannot observe from Marco’s behavior at home whether a given illness is producing physiologic demand within the maintenance reserve or approaching the threshold where that reserve is insufficient. The early clinical features of adrenal insufficiency during illness — increased fatigue, persistent nausea or vomiting, poor appetite, abdominal pain, prolonged fever without a specific septic source, unusual lethargy — are identical to the normal features of a moderately ill four-year-old with a viral infection or otitis media. The distinction between “normally ill” and “insufficient cortisol reserve” is not visible on the face of a child at home. It becomes visible when crisis is established: when the blood pressure falls and does not respond to fluids, when the blood glucose drops to 35 mg/dL, when the altered consciousness begins. At that point, intravenous or intramuscular hydrocortisone 50 mg/m² must be administered within thirty minutes for the outcome to be good. At home, the window to administer the stress dose orally is before any of those visible crisis signs appear.

The three times daily dose that constitutes the oral stress protocol provides approximately 18 mg/m²/day of hydrocortisone equivalent — within the range of a physiologic stress cortisol surge. It costs Marco one additional pill at each of three doses, one additional dose from the bottle in the cabinet, and two to three days until the illness resolves. The cost-benefit calculation does not resemble a difficult clinical judgment. Nurse Carmen frames it for Roberto: the two illnesses Marco “did fine” in are not evidence the protocol is unnecessary — they are evidence that those two illnesses happened to be mild enough. The protocol exists for the illness that is not quite mild enough, and neither Roberto nor the clinic can tell in advance which illness that will be.

Sofia Mendez-Vásquez, 9 years old, Dallas, Texas — growth hormone deficiency post-craniopharyngioma, recombinant GH 0.35 mg/kg/week, height velocity 8.6 cm/year at 12 months on treatment, mother requesting discontinuation

Sofia presented at age eight years and three months with a six-month history of progressive headache and two months of visual field limitation on informal testing. Her growth chart, reviewed at presentation, showed height velocity of 2.8 cm/year for the preceding year — significantly below the expected 5.5 to 6.5 cm/year for her age. MRI with contrast showed a suprasellar cystic and solid mass 3.2 × 2.8 × 2.4 cm with peripheral calcifications, consistent with adamantinomatous craniopharyngioma. Ophthalmology confirmed bitemporal hemianopia from optic chiasm compression.

Gross total resection was achieved via extended transsphenoidal approach eight months ago. Pathology confirmed adamantinomatous craniopharyngioma with a CTNNB1 exon 3 activating mutation (nuclear β-catenin accumulation on immunohistochemistry). Post-operative MRI at three months: no residual tumor; pituitary stalk thickening at the resection margin consistent with post-surgical changes; pituitary gland volume reduced compared to pre-operative imaging.

Post-surgical pituitary function testing at four months: insulin tolerance test (the gold-standard provocative test for GH sufficiency, which induces hypoglycemia to confirm adequate ACTH and GH secretory reserve) — adequate hypoglycemia achieved (glucose nadir 32 mg/dL); cortisol peak 4.2 mcg/dL (severely insufficient; normal >18 mcg/dL, confirming central adrenal insufficiency); GH peak 0.4 ng/mL (severely deficient; normal >10 ng/mL; severe GH deficiency defined as peak <3 ng/mL). Additional testing confirmed central hypothyroidism (low-normal TSH with low free T4), central diabetes insipidus (treated with desmopressin), and prepubertal gonadotropin levels consistent with central hypogonadism. Sofia now takes hydrocortisone, levothyroxine, desmopressin, and GH — each replacing a pituitary hormone axis that was destroyed by the tumor and surgery.

Recombinant human GH (somatropin) at 0.35 mg/kg/week divided over six days per week via subcutaneous injection was started three months after surgery once the pituitary function evaluation was complete. Baseline (pre-GH) IGF-1: 42 ng/mL (SDS −3.1 for age and sex). Twelve months later: IGF-1 198 ng/mL (SDS −0.4); height velocity 8.6 cm/year; height SDS improved from −2.8 to −1.9.

Ana Mendez-Torres, forty, nurse’s aide, arrives today delighted with Sofia’s growth and tired of the daily injections. She has researched online and found that some children with temporary pituitary problems recover pituitary function. She asks directly: Sofia is growing better than normal children her age. She must have recovered. Can the GH be stopped?

Nurse Patricia Vargas-Espinoza needs to explain what craniopharyngioma does to somatotroph cells and why the recovery Ana read about applies to different conditions entirely.

The anterior pituitary gland contains five hormonally specialized cell types: somatotrophs (GH, 40–50% of cell mass), corticotrophs (ACTH, 15–20%), thyrotrophs (TSH, 5%), gonadotrophs (FSH/LH, 10–15%), and lactotrophs (prolactin, 10–20%). Somatotrophs are concentrated in the lateral wings of the anterior pituitary and depend on both GHRH delivery via the portal blood supply from hypothalamic arcuate nucleus neurons and ghrelin signaling for normal pulsatile GH secretion.

Craniopharyngioma — an adamantinomatous epithelial tumor arising from Rathke’s pouch remnants in the suprasellar region — damages somatotrophs through two mechanisms that operated concurrently in Sofia’s case. First, as the tumor grew from its suprasellar origin to 3.2 cm, it compressed the pituitary stalk from above, impairing portal blood flow carrying GHRH from hypothalamic neurons to anterior pituitary somatotrophs. The pressure-ischemia produced by months of progressive compression results in somatotroph dysfunction and eventually cell death through ischemic necrosis. Second, transsphenoidal surgical resection of the tumor required cutting through and retracting tissue in the immediate vicinity of the pituitary stalk. The stalk thickening visible on post-operative MRI represents post-surgical injury at the stalk, with disruption of portal vessels. The pituitary gland volume reduction visible on imaging reflects cell loss.

Adult anterior pituitary cells have minimal regenerative capacity. Unlike the thyroid, which has some follicular progenitor activity, the mature anterior pituitary does not have a meaningful population of somatotroph progenitors that proliferate and replace lost cells after surgical injury. The post-operative ITT peak GH of 0.4 ng/mL at four months from surgery reflects near-complete absence of functional somatotroph cells. This result places Sofia in the category of severe GH deficiency — a category where spontaneous recovery does not occur, because the cells that would need to recover are absent. The “temporary pituitary problems” that sometimes recover after pituitary surgery describe either mild deficiencies from edema that resolves or partial deficiencies in conditions that did not destroy the somatotroph cell population. Sofia’s ITT result at four months post-surgery, after any post-surgical edema would have resolved, establishes that her somatotroph cell population is permanently non-functional.

The GH axis operates through a hepatic IGF-1 intermediary: GH binds the GH receptor (GHR) on hepatocytes, activating the intracellular Janus kinase 2 (JAK2) through receptor dimerization and transphosphorylation. JAK2 phosphorylates STAT5b, which dimerizes and translocates to the hepatocyte nucleus where it binds GAS elements in the IGF-1 gene promoter and activates IGF-1 transcription. Hepatocytes secrete IGF-1 into the circulation, where it is transported bound to IGF binding proteins — predominantly IGFBP-3 — to target tissues. At the epiphyseal growth plates in long bones, IGF-1 binds IGF1R on chondrocytes in the proliferative zone, activating the RAS-MAPK and PI3K-AKT pathways that drive chondrocyte proliferation, hypertrophy, and extracellular matrix production. The hypertrophic zone expansion that follows is the molecular basis of longitudinal bone growth.

IGF-1 as a clinical measurement reflects current GH signaling: the hepatic IGF-1 production rate responds to the circulating GH stimulus within a matter of days. Sofia’s IGF-1 of 198 ng/mL at SDS −0.4 after twelve months of GH therapy reflects the hepatocyte JAK2-STAT5 pathway being continuously activated by the daily somatropin injections. Her IGF-1 before GH therapy was 42 ng/mL at SDS −3.1 — the direct measurement of what her pituitary’s somatotroph output was contributing. If GH injections stop, hepatocyte GHR stimulation ceases. JAK2-STAT5 activation falls. IGF-1 gene transcription returns to basal levels. Serum IGF-1 falls from 198 ng/mL to approximately 42 ng/mL within four to six weeks — the time required for the IGFBP-3-bound IGF-1 pool to turn over. The epiphyseal growth plates, no longer receiving the IGF-1 signal that drives chondrocyte proliferation, reduce their longitudinal growth activity. Height velocity returns to approximately 2.8 cm/year within three to six months. Sofia’s 8.6 cm/year is the GH working. The moment the injections stop, it stops working.

Sofia is nine years old. Girls reach epiphyseal closure on average between ages fifteen and seventeen, with earlier closure associated with early puberty — which Sofia may experience earlier than typical given her pituitary dysfunction and the need for future sex hormone replacement. She has a minimum of six and possibly eight years of GH-dependent linear growth remaining. At her current 8.6 cm/year height velocity she would gain approximately 52 to 69 cm of additional height over six to eight years. At the GH-deficient rate of 2.8 cm/year she would gain approximately 17 to 22 cm. The difference — 30 to 47 cm — represents most of her remaining linear growth potential. Even accounting for the fact that catch-up growth rate typically decreases over years of GH therapy as height SDS approaches the target, the difference in final adult height between treated and untreated GH deficiency beginning at age nine is approximately 15 to 20 cm in clinical series of craniopharyngioma patients.

Beyond height, GH therapy throughout the remaining growth years drives bone mineral density accrual through IGF-1-stimulated osteoblast activity and cortical bone modeling. Peak bone mass is achieved between ages twenty-five and thirty. The bone mineral density achieved by epiphyseal closure determines fracture risk for the subsequent six decades of life. GH deficiency during adolescence, even without other risk factors, reduces peak bone mass to a degree that is not fully recoverable by initiating GH treatment after growth completion. The injections Ana finds burdensome are producing bone that Sofia will depend on at age fifty.

Nurse Patricia addresses Ana’s mention of cost and insurance: there are specific patient assistance programs for craniopharyngioma-related GH deficiency, and the endocrinology team can initiate that enrollment. The daily injections are real work. The concern about Sofia’s comfort is real. Neither changes what the somatotroph cells destroyed by the tumor and surgery can produce, which is zero. The 8.6 cm/year that Ana celebrates as evidence the injections can stop is exactly the measurement that confirms they cannot. It is the injections reporting back, in the most direct language available, that they are doing exactly what Sofia needs.

The three scenarios in this post share a structural pattern across the pediatric endocrinology clinic: families who observe a positive clinical measurement — a normal TSH, two illnesses survived without crisis, a child growing at a completely normal rate — and reason from that positive measurement toward reducing or stopping an intervention, not understanding that the positive measurement is either produced by the intervention working correctly or reflects the temporary absence of a demand that the intervention exists to meet. Isabella’s TSH of 1.8 is the levothyroxine dose calibrated correctly, not evidence of thyroid gland activity; stopping levothyroxine removes the only source of T4 Isabella will ever have and produces overt hypothyroidism within weeks in a brain still actively myelinating. Marco’s two survived illnesses are evidence that those two specific illnesses did not demand more than the maintenance hydrocortisone reserve could cover, not that CYP21A2 deficiency has changed or that the stress-dosing protocol is conservative; the next illness that demands slightly more will encounter the same cortisol synthesis capability, which remains zero. Sofia’s 8.6 cm/year growth velocity is IGF-1 from daily GH injections driving epiphyseal chondrocyte proliferation, not pituitary recovery; somatotroph cells destroyed by craniopharyngioma compression and surgical resection do not regenerate, and stopping injections removes the only GH source her body has and returns height velocity to 2.8 cm/year within months.

The nurse who understands these mechanisms can reframe each clinical conversation from “the result looks normal, so the treatment seems unnecessary” to “the result looks normal because the treatment is working, and the normal result disappears when the treatment stops.” TSH 1.8 means the levothyroxine is exactly right — it would be above 50 without it, and Isabella’s brain development depends on it staying at 1.8 through the active myelination period. Two survived febrile illnesses mean those illnesses were mild enough — the cortisol synthesis in Marco’s adrenal gland is the same zero it was during both illnesses, and the protocol that was not needed for those illnesses is the mechanism that prevents crisis in the illness that is not quite mild enough. Growth at 8.6 cm/year means the GH injections are providing the hormone Sofia’s permanently non-functional somatotrophs cannot — it is the best possible evidence that the injections are working correctly, and stopping them returns height velocity to 2.8 cm/year and initiates the skeletal deficit that accumulates over the remaining six to eight years of growth.

Six key Spanish phrases for the pediatric endocrinology clinic

El TSH normal de Isabella NO significa que su tiroides está funcionando — significa que la dosis de levotiroxina está calibrada correctamente. La tiroides de Isabella no existe: el estudio de imagen confirmó que no hay células que produzcan hormona tiroidea. La levotiroxina ES la hormona tiroidea, no un suplemento para ayudar a una tiroides débil. Si la paramos, la T4 baja en dos a tres semanas, el TSH sube por encima de 10 en un mes, y el cerebro de Isabella, que todavía está completando la mielinización hasta los ocho a diez años, pierde la señal hormonal que ese proceso requiere. — Isabella's normal TSH does NOT mean her thyroid is working — it means the levothyroxine dose is calibrated correctly. Isabella's thyroid does not exist: the imaging study confirmed there are no cells that produce thyroid hormone. Levothyroxine IS the thyroid hormone, not a supplement to help a weak thyroid. If we stop it, T4 falls in two to three weeks, TSH rises above 10 in a month, and Isabella's brain, which is still completing myelination until age eight to ten, loses the hormonal signal that process requires.
El TSH que la hipofófisis produce depende solo de cuánta hormona tiroidea hay en la sangre en ese momento — no sabe de dónde viene. Si la dosis de levotiroxina es correcta, el TSH está normal. Si no hay levotiroxina y tampoco hay tiroides, el TSH estaría por encima de 50. El número 1.8 le dice a la hipofófisis que la señal está bien. No le dice nada sobre una tiroides que se esté recuperando, porque no hay tiroides que recuperar. — The TSH the pituitary produces depends only on how much thyroid hormone is in the blood at that moment — it does not know where it comes from. If the levothyroxine dose is correct, the TSH is normal. If there is no levothyroxine and also no thyroid, the TSH would be above 50. The number 1.8 tells the pituitary the signal is right. It does not say anything about a thyroid recovering, because there is no thyroid to recover.
La deficiencia de 21-hidroxilasa de Marco le impide permanentemente producir cortisol. Cuando hay fiebre, el cuerpo normal produce de tres a diez veces más cortisol para mantener la presión arterial y el azúcar en sangre. El cuerpo de Marco no puede hacer eso — la enzima no existe. Las dos enfermedades anteriores probablemente fueron lo suficientemente leves como para que la dosis de mantenimiento alcanzara. La próxima que exija más tendrá un resultado diferente si no triplicamos la dosis: hipotensón que no responde a líquidos e hipoglucemia pueden ocurrir en horas. — Marco's 21-hydroxylase deficiency permanently prevents him from producing cortisol. When there is fever, the normal body produces three to ten times more cortisol to maintain blood pressure and blood sugar. Marco's body cannot do that — the enzyme does not exist. The two previous illnesses were probably mild enough that the maintenance dose was sufficient. The next one that demands more will have a different result if we do not triple the dose: hypotension that does not respond to fluids and hypoglycemia can occur within hours.
Roberto no puede ver desde casa si la demanda de una enfermedad está dentro del nivel que la dosis de mantenimiento puede cubrir o si se está acercando al umbral de una crisis. Los signos tempranos de una insuficiencia suprarrenal durante una enfermedad — más cansancio, náuseas, dolor abdominal, fiebre prolongada — son idénticos a los de cualquier niño enfermo. La distinción se vuelve visible solo cuando la crisis ya está establecida y se necesita hidrocortisona IV inmediata. El protocolo de dosis de estrés existe para que eso no llegue a ocurrir. — Roberto cannot see from home whether the demand of an illness is within the level the maintenance dose can cover or is approaching the crisis threshold. The early signs of adrenal insufficiency during illness — more fatigue, nausea, abdominal pain, prolonged fever — are identical to those of any sick child. The distinction only becomes visible when the crisis is already established and immediate IV hydrocortisone is needed. The stress dose protocol exists so that does not happen.
Las células productoras de hormona de crecimiento de Sofia fueron destruidas por el tumor y la cirugía. La prueba de estimulación confirmó que la hipofófisis produce menos del 5% de la hormona de crecimiento necesaria — esencialmente nada. Esas células no se regeneran. El crecimiento de 8.6 centímetros al año que la mamá está viendo ES las inyecciones funcionando. Es exactamente la evidencia de que la dosis está correcta. Si paramos las inyecciones, el IGF-1 cae a los niveles de antes del tratamiento en seis semanas y la velocidad de crecimiento vuelve a 2.8 centímetros al año en pocos meses. — Sofia's growth hormone-producing cells were destroyed by the tumor and surgery. The stimulation test confirmed that the pituitary produces less than 5% of the needed growth hormone — essentially nothing. Those cells do not regenerate. The 8.6 centimeters per year growth the mom is seeing IS the injections working. It is exactly the evidence that the dose is correct. If we stop the injections, IGF-1 falls to pre-treatment levels in six weeks and growth velocity returns to 2.8 centimeters per year within a few months.
Sofia tiene nueve años y sus huesos todavía van a crecer por seis a ocho años más. A 2.8 centímetros al año llegaría a su estatura final con 15 a 20 centímetros menos de lo que le corresponde según su familia. Además, la hormona de crecimiento durante la adolescencia construye la densidad mineral ósea que Sofia necesitará toda la vida adulta. El crecimiento normal que la familia celebra es la mejor evidencia de que las inyecciones están funcionando exactamente bien — no de que ya no las necesita. — Sofia is nine years old and her bones are still going to grow for six to eight more years. At 2.8 centimeters per year she would reach her final height 15 to 20 centimeters below what is expected for her family. Also, growth hormone during adolescence builds the bone mineral density Sofia will need for her entire adult life. The normal growth the family celebrates is the best evidence that the injections are working exactly well — not that she no longer needs them.

For related conditions in the pediatric endocrinology setting, see Spanish for pediatric peroxisomal disorders clinic nurses (covering X-ALD VLCFA accumulation and the adrenal insufficiency that develops independently of neurological disease, requiring annual ACTH stimulation testing), Spanish for pediatric congenital hyperinsulinism clinic nurses (covering diazoxide continuation when glucose is normal, focal CHI surgery versus octreotide, and nocturnal CGM after UCCS), and Spanish for pediatric organic acidemia clinic nurses (covering adrenal insufficiency in the context of metabolic decompensation and the role of stress dosing in preventing metabolic crisis).